Rainer Hintenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rainer Hintenberger has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Clemens Steinwender
Department of Cardiology, Kepler University Hospital, Medical Faculty, Johannes Kepler University , Krankenhausstr. 9, 4020 Linz, and Altenberger Str. 69, 4040 Linz
2 shared publications - Herwig Pieringer
Section of Rheumatology, 2nd Department of Medicine, General Hospital Linz, Linz, Austria
2 shared publications Agnes Falkinger
Academic Research Unit, 2nd Department of Internal Medicine, Kepler University Hospital, Med Campus III, Krankenhausstr. 9, 4020, Linz, Austria
1 shared publication- Barbara Affenzeller
Department for Internal Medicine II, Kepler University Hospital GmbH, Johannes Kepler University Linz, Linz, Austria
1 shared publication - Barbara Wichert-Schmitt
Department of Cardiology and Medical Intensive Care, Kepler University Hospital, Johannes Kepler University , 4020 Linz
1 shared publication - Erich Pohanka
Kepler University Hospital
1 shared publication
Latest Publications
- Open Access
- 13 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (9) , ytaf388
Pericardial tamponade in pregnancy due to undiagnosed systemic lupus erythematosus: a case report
Background: Pericardial tamponade during pregnancy is rare. Diagnosis of pericardial effusion can easily be made by echocardiography. Thorough clinical assessment, laboratory testing and advanced cardiac imaging are necessary to identify the underlying cause of pericardial effusion and rule out other causes of chest pain. Most diagnostic tests and therapeutic measures are safe during pregnancy. Systemic lupus erythematosus can be diagnosed by integrating clinical features and serologic testing. Certain autoantibodies increase the risk for adverse pregnancy events and multi-disciplinary team care is essential for a favourable pregnancy outcome. Case summary: A 37-year-old previously healthy woman presented with chest pain at 24 weeks gestational age. Echocardiography revealed a large pericardial effusion, which quickly progressed to pericardial tamponade. The woman required urgent thoracoscopic pericardial drainage as the gravid uterus impaired subcostal or apical access for pericardiocentesis. The surgery was performed without complications. Serologic testing was positive for antinuclear antibodies. Rheumatology assessment revealed further clinical features of systemic lupus erythematosus, which established the diagnosis. After initiation of treatment with hydroxychloroquine and prednisone the chest pain resolved and pericardial effusion did not recur. The twin fetuses were monitored regularly by the obstetrical team and no adverse pregnancy events occurred. Conclusion: Cardiologists may be the first to detect pericardial effusion as a clinical feature of rheumatologic disease. Multi-disciplinary team care leads to good pregnancy outcomes for mother and child.
- 13 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (9) , ytaf388
Open AccessPericardial tamponade in pregnancy due to undiagnosed systemic lupus erythematosus: a case report
Background: Pericardial tamponade during pregnancy is rare. Diagnosis of pericardial effusion can easily be made by echocardiography. Thorough clinical assessment, laboratory testing and advanced cardiac imaging are necessary to identify the underlying cause of pericardial effusion and rule out other causes of chest pain. Most diagnostic tests and therapeutic measures are safe during pregnancy. Systemic lupus erythematosus can be diagnosed by integrating clinical features and serologic testing. Certain autoantibodies increase the risk for adverse pregnancy events and multi-disciplinary team care is essential for a favourable pregnancy outcome. Case summary: A 37-year-old previously healthy woman presented with chest pain at 24 weeks gestational age. Echocardiography revealed a large pericardial effusion, which quickly progressed to pericardial tamponade. The woman required urgent thoracoscopic pericardial drainage as the gravid uterus impaired subcostal or apical access for pericardiocentesis. The surgery was performed without complications. Serologic testing was positive for antinuclear antibodies. Rheumatology assessment revealed further clinical features of systemic lupus erythematosus, which established the diagnosis. After initiation of treatment with hydroxychloroquine and prednisone the chest pain resolved and pericardial effusion did not recur. The twin fetuses were monitored regularly by the obstetrical team and no adverse pregnancy events occurred. Conclusion: Cardiologists may be the first to detect pericardial effusion as a clinical feature of rheumatologic disease. Multi-disciplinary team care leads to good pregnancy outcomes for mother and child.
- Open Access
- 7 July 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (10) , 2621-2633
Cardiovascular risk in axial spondyloarthritis—a systematic review
Cardiovascular manifestations are common in patients suffering axial spondyloarthritis and can result in substantial morbidity and disease burden. To give an overview of this important aspect of axial spondyloarthritis, we conducted a systematic literature search of all articles published between January 2000 and 25 May 2023 on cardiovascular manifestations. Using PubMed and SCOPUS, 123 out of 6792 articles were identified and included in this review. Non-radiographic axial spondyloarthritis seems to be underrepresented in studies; thus, more evidence for ankylosing spondylitis exists. All in all, we found some traditional risk factors that led to higher cardiovascular disease burden or major cardiovascular events. These specific risk factors seem to be more aggressive in patients with spondyloarthropathies and have a strong connection to high or long-standing disease activity. Since disease activity is a major driver of morbidity, diagnostic, therapeutic, and lifestyle interventions are crucial for better outcomes. Key Points• Several studies on axial spondyloarthritis and associated cardiovascular diseases have been conducted in the last few years addressing risk stratification of these patients including artificial intelligence.• Recent data suggest distinct manifestations of cardiovascular disease entities among men and women which the treating physician needs to be aware of.• Rheumatologists need to screen axial spondyloarthritis patients for emerging cardiovascular disease and should aim at reducing traditional risk factors like hyperlipidemia, hypertension, and smoking as well as disease activity.
- 7 July 2023
- Published by Springer Nature in Clinical Rheumatology
- Vol. 42 (10) , 2621-2633
Open AccessCardiovascular risk in axial spondyloarthritis—a systematic review
Cardiovascular manifestations are common in patients suffering axial spondyloarthritis and can result in substantial morbidity and disease burden. To give an overview of this important aspect of axial spondyloarthritis, we conducted a systematic literature search of all articles published between January 2000 and 25 May 2023 on cardiovascular manifestations. Using PubMed and SCOPUS, 123 out of 6792 articles were identified and included in this review. Non-radiographic axial spondyloarthritis seems to be underrepresented in studies; thus, more evidence for ankylosing spondylitis exists. All in all, we found some traditional risk factors that led to higher cardiovascular disease burden or major cardiovascular events. These specific risk factors seem to be more aggressive in patients with spondyloarthropathies and have a strong connection to high or long-standing disease activity. Since disease activity is a major driver of morbidity, diagnostic, therapeutic, and lifestyle interventions are crucial for better outcomes. Key Points• Several studies on axial spondyloarthritis and associated cardiovascular diseases have been conducted in the last few years addressing risk stratification of these patients including artificial intelligence.• Recent data suggest distinct manifestations of cardiovascular disease entities among men and women which the treating physician needs to be aware of.• Rheumatologists need to screen axial spondyloarthritis patients for emerging cardiovascular disease and should aim at reducing traditional risk factors like hyperlipidemia, hypertension, and smoking as well as disease activity.
- 1 November 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (1) , 37-50
Cardiovascular disease in patients with autoinflammatory syndromes
Autoinflammatory syndromes (AIS) are characterized by recurring events of inflammation, leading to a variety of organ manifestations and fever attacks. A subgroup of AIS is commonly referred to as hereditary periodic fever syndromes (HPFS). There is substantial evidence that autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are strongly associated with cardiovascular morbidity and mortality. The link between AIS and cardiovascular disease is not that clear, even if the concept of continuous inflammation as a risk factor for cardiovascular disease is widely accepted. Research on the association of AIS and cardiovascular disease is increasing within the last years. In this review, we will discuss the association of several AIS with cardiovascular disease. Based on the rarity of some entities, lack of data, however, led to exclusion of some rare AIS. Especially, for Behcet’s disease (BD), adult-onset Still’s disease (AOSD), and Familial Mediterranean fever (FMF), there is an association with a number of cardiovascular abnormalities. BD is the AIS, which is most strongly associated with manifestation in the arterial and venous system. AOSD is strongly associated with cardiac inflammation (peri-/myocarditis). FMF patients are likely to suffer from serositis. Of note, there seems to be a link between variants of AOSD as well as FMF and idiopathic recurrent acute pericarditis.
- 1 November 2017
- Published by Springer Nature in Rheumatology International
- Vol. 38 (1) , 37-50
Cardiovascular disease in patients with autoinflammatory syndromes
Autoinflammatory syndromes (AIS) are characterized by recurring events of inflammation, leading to a variety of organ manifestations and fever attacks. A subgroup of AIS is commonly referred to as hereditary periodic fever syndromes (HPFS). There is substantial evidence that autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are strongly associated with cardiovascular morbidity and mortality. The link between AIS and cardiovascular disease is not that clear, even if the concept of continuous inflammation as a risk factor for cardiovascular disease is widely accepted. Research on the association of AIS and cardiovascular disease is increasing within the last years. In this review, we will discuss the association of several AIS with cardiovascular disease. Based on the rarity of some entities, lack of data, however, led to exclusion of some rare AIS. Especially, for Behcet’s disease (BD), adult-onset Still’s disease (AOSD), and Familial Mediterranean fever (FMF), there is an association with a number of cardiovascular abnormalities. BD is the AIS, which is most strongly associated with manifestation in the arterial and venous system. AOSD is strongly associated with cardiac inflammation (peri-/myocarditis). FMF patients are likely to suffer from serositis. Of note, there seems to be a link between variants of AOSD as well as FMF and idiopathic recurrent acute pericarditis.
- 14 September 2017
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (11) , 2439-2445
RABBIT risk score and ICU admission due to infection in patients with rheumatoid arthritis
Rheumatoid arthritis (RA) patients are at increased risk of infection. Aim of the present study was to investigate whether RA patients admitted to an intensive care unit (ICU) due to infection have higher Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk scores compared to control RA patients. Seventy-four RA patients (32.4% male) admitted to an ICU due to infection (from January 2002 to December 2013) and 74 frequency-matched control RA patients (16.2% male) were included in this cross-sectional study. There was strong evidence for a higher RABBIT risk score in ICU patients (median 2.0; IQR 1.3–3.2) as compared to controls (1.3; IQR 0.8–2.0; p < 0.0001). Traditional disease-modifying anti-rheumatic drugs (DMARDs) (82.4 vs 64.9%; p = 0.015) and biological DMARDs (28.4 vs 14.9%; p = 0.012) were more frequently given to RA patients without ICU admission. Glucocorticoid users were more frequently found in the ICU group (51.4 vs 31.1%; p = 0.012). In a multivariable analysis tDMARD use was associated with lower (OR 0.38; 95% CI 0.15–0.93; p = 0.034) and glucocorticoid use with borderline higher odds of ICU admission (OR 2.05; 95% CI 0.92–4.58; p = 0.078). Chronic obstructive pulmonary disease (OR 2.89; 95% CI 1.10–7.54; p = 0.03), chronic kidney disease (OR 16.08; 95% CI 2.00–129.48; p = 0.009), and age category (OR 2.67; 95% CI 1.46–4.87; p = 0.001) were strongly associated with ICU admission. There was a strong trend towards higher odds of ICU admission with increasing RABBIT risk score. Use of tDMARDs was associated with lower odds of ICU admission. In an adjusted analysis, bDMARDs were not associated with ICU admission. COPD, CKD, and age were strong risk factors for ICU admission.
- 14 September 2017
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (11) , 2439-2445
RABBIT risk score and ICU admission due to infection in patients with rheumatoid arthritis
Rheumatoid arthritis (RA) patients are at increased risk of infection. Aim of the present study was to investigate whether RA patients admitted to an intensive care unit (ICU) due to infection have higher Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk scores compared to control RA patients. Seventy-four RA patients (32.4% male) admitted to an ICU due to infection (from January 2002 to December 2013) and 74 frequency-matched control RA patients (16.2% male) were included in this cross-sectional study. There was strong evidence for a higher RABBIT risk score in ICU patients (median 2.0; IQR 1.3–3.2) as compared to controls (1.3; IQR 0.8–2.0; p < 0.0001). Traditional disease-modifying anti-rheumatic drugs (DMARDs) (82.4 vs 64.9%; p = 0.015) and biological DMARDs (28.4 vs 14.9%; p = 0.012) were more frequently given to RA patients without ICU admission. Glucocorticoid users were more frequently found in the ICU group (51.4 vs 31.1%; p = 0.012). In a multivariable analysis tDMARD use was associated with lower (OR 0.38; 95% CI 0.15–0.93; p = 0.034) and glucocorticoid use with borderline higher odds of ICU admission (OR 2.05; 95% CI 0.92–4.58; p = 0.078). Chronic obstructive pulmonary disease (OR 2.89; 95% CI 1.10–7.54; p = 0.03), chronic kidney disease (OR 16.08; 95% CI 2.00–129.48; p = 0.009), and age category (OR 2.67; 95% CI 1.46–4.87; p = 0.001) were strongly associated with ICU admission. There was a strong trend towards higher odds of ICU admission with increasing RABBIT risk score. Use of tDMARDs was associated with lower odds of ICU admission. In an adjusted analysis, bDMARDs were not associated with ICU admission. COPD, CKD, and age were strong risk factors for ICU admission.